TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A University of Oulu-led study of 29 healthy adults found that a combination of temporarily blood-pressure-lowering medication and whole-body vibration was associated with changes in brain fluid flow and higher blood levels of several brain-derived proteins. The researchers say this may indicate increased protein clearance, but the study did not test whether the approach prevents or treats dementia.
A study led by the University of Oulu found that a treatment combining temporary blood-pressure reduction with rhythmic whole-body vibration was associated with increased movement of brain-derived proteins into participants’ blood. The research involved 29 healthy adults and offers early evidence that the brain’s waste-clearance processes may be influenced while people are awake, but it does not show that the treatment prevents or slows dementia.
Researchers used blood-pressure-lowering medication alongside vibration intended to stimulate mechanosensitive Piezo1 channels in blood vessels. They assessed the effects with multimodal MRI, physiological measurements and blood-based biomarkers. After treatment, blood levels of several soluble proteins associated with the brain—including beta-amyloid 40 and 42, and GFAP—rose. MRI measurements also showed changes in fluid movement and around large veins in the brain.
The team interpreted the blood changes and imaging results as evidence consistent with increased movement of proteins out of the brain. The study’s lead researcher, Johanna Tuunanen, said the results suggest harmful proteins were cleared more efficiently than usual. A rise in blood levels, however, is an indirect measure: the findings do not establish how much protein was removed, whether the effect lasts, or whether it changes disease risk.
The paper, titled “Vasomechanic treatment is associated with increased efflux of human brain proteins,” was published in Nature Communications on November 3. The study was conducted by researchers at the University of Oulu and Oulu University Hospital. Its participants were healthy adults, rather than people with dementia or early memory impairment.
A Possible Route to Brain Clearance
Alzheimer’s disease and other dementias are associated with the gradual accumulation of harmful proteins in the brain. The study examines whether processes that help move soluble proteins out of the brain can be affected before deposits form. That makes the work relevant to future research on early intervention, but it is not evidence that this treatment prevents dementia or improves memory.
The distinction between a biological signal and a patient benefit is important. Researchers measured changes in fluid flow and proteins in blood; they did not track dementia diagnoses, cognitive decline or long-term outcomes. Any potential application would require further studies to establish safety, effectiveness and suitable patients.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
As an affiliate, we earn on qualifying purchases.
How the Treatment Was Designed
The brain’s clearance processes are more active during sleep. As people fall asleep, blood pressure typically drops and slow blood-vessel and breathing-related pulsations strengthen, helping move cerebrospinal fluid through brain tissue. The Oulu team said the medication in its study strengthened slow brain pulsations, in a way that partly resembled changes previously observed during sleep.
The vibration component was based on earlier animal research linking activation of Piezo1 channels to changes in vessel function and meningeal lymphatic flow. Those animal findings provided a rationale for testing the combined approach in people; they do not establish that the same effects will prevent or treat human dementia. The current human study tested short-term biological responses in a small group of healthy volunteers.
Questions Before Patient Trials
The report does not establish whether the measured changes represent a lasting increase in brain clearance, or whether the proteins detected in blood came from the specific clearance route proposed by the researchers. The study also does not show whether treatment changes protein deposits in brain tissue or affects cognitive function.
Because the trial included only 29 healthy adults, the findings cannot establish how the approach would work in older people or patients with early memory impairment. The source material does not provide details on the duration of follow-up, the size of the observed effects, or the risks of repeating the intervention. Those questions will need to be addressed before the findings can support claims about dementia prevention or treatment.
Follow-Up Studies in Patients
Kiviniemi said the team is planning follow-up research with other experts to examine possible benefits in people with early-stage memory impairment. The next studies will need to test whether the short-term changes seen in healthy volunteers can be reproduced in patient groups and whether they lead to meaningful outcomes over time.
Until those results are available, the treatment remains an experimental research approach. No timetable, trial design or patient results were specified in the report. The immediate next milestone is further investigation of the intervention’s effects and safety, not a confirmed clinical use.
Key Questions
What treatment did the researchers test?
They combined medication that temporarily lowers blood pressure with rhythmic whole-body vibration designed to stimulate Piezo1 channels in blood vessels.
Did the study show that the treatment prevents dementia?
No. It measured short-term changes in brain-fluid movement and blood levels of brain-derived proteins in healthy adults. It did not test dementia prevention, treatment or cognitive outcomes.
What happened to protein levels in participants’ blood?
Blood levels of several soluble proteins, including beta-amyloid 40 and 42 and GFAP, increased after treatment. The researchers said this was consistent with greater movement of proteins out of the brain, but it is not by itself proof of a long-term health benefit.
What happens next?
The researchers said they are planning follow-up studies, including research involving people with early-stage memory impairment. The report did not give a timetable or details of the planned trials.
Source: news-medical.net
